Loading...
•
Sep 30, 2024
C4 Therapeutics Q3 2024 Earnings Report
C4 Therapeutics reported financial results for the third quarter ended September 30, 2024, and recent business highlights.
Key Takeaways
C4 Therapeutics reported Q3 2024 revenue of $15.4 million compared to $11.1 million for Q3 2023. Net loss for the quarter was $24.7 million, or $0.35 per share, compared to a net loss of $27.0 million, or $0.55 per share, for the third quarter of 2023. Cash, cash equivalents and marketable securities totaled $284.4 million as of September 30, 2024, expected to provide runway into 2027.
Cemsidomide Phase 1/2 trial in Multiple Myeloma and non-Hodgkin’s Lymphoma continues to progress; data from both indications to be presented at ASH Annual Meeting in San Diego, CA.
Initial Monotherapy CFT1946 Phase 1 data demonstrated well-tolerated safety profile and early evidence of anti-tumor activity; Phase 1/2 Trial Continues to Progress with Multiple Data Readouts Expected in 2025.
Paige Mahaney, Ph.D. was appointed as Chief Scientific Officer.
Cash, cash equivalents and marketable securities of $284.4 million as of September 30, 2024; Expected to Provide Runway into 2027.
Revenue by Segment
Forward Guidance
C4T expects that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund planned operating expenses and capital expenditures into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...